new FDA advisory on the erythropoietin analogues Procrit, Epogen, and Aranesp

Read important updated information from the FDA

You'll hear about a new FDA advisory on the erythropoietin analogues Procrit, Epogen, and Aranesp.

It's based on evidence of an increase in death and cardiovascular events when these drugs are used to boost hemoglobin above 12 g/dL.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote